Mehmet A Baysal

Publication Activity (10 Years)

Years Active: 2023-2024
Publications (10 Years): 8

Top Topics

Advanced Cancer

End Stage Renal Disease

Prognostic Factors

Top Venues

Human vaccines & immunotherapeutics

Nature reviews. Clinical oncology

International journal of molecular sciences

This page only lists publications with an associated author ORCID identifier.

Publications

Benigno C Valdez, Apostolia-Maria Tsimberidou, Bin Yuan, Mehmet A Baysal, Abhishek Shankar, Clark R Andersen, Borje S Andersson
Synergistic Cytotoxicity of Histone Deacetylase and Poly-ADP Ribose Polymerase Inhibitors and Decitabine in Breast and Ovarian Cancer Cells: Implications for Novel Therapeutic Combinations. International journal of molecular sciences 25 (17) (2024)
Apostolia-Maria Tsimberidou, Mehmet A Baysal, Abhishek Shankar, Borje S Andersson
Autologous engineered T cell receptor therapy in advanced cancer. Human vaccines & immunotherapeutics 19 (3) (2023)
Apostolia M Tsimberidou, Michael Kahle, Henry Hiep Vo, Mehmet A Baysal, Amber Johnson, Funda Meric-Bernstam
Molecular tumour boards - current and future considerations for precision oncology. Nature reviews. Clinical oncology (2023)
Apostolia-Maria Tsimberidou, Mehmet A Baysal, Abhishek Shankar, Borje S Andersson
Autologous engineered T cell receptor therapy in advanced cancer. Human vaccines & immunotherapeutics 19 (3) (2023)
Apostolia-Maria Tsimberidou, Mehmet A Baysal, Abhishek Shankar, Borje S Andersson
Autologous engineered T cell receptor therapy in advanced cancer. Human vaccines & immunotherapeutics 19 (3) (2023)
I-Wen Song, Henry Hiep Vo, Ying-Shiuan Chen, Mehmet A Baysal, Michael Kahle, Amber Johnson, Apostolia M Tsimberidou
Precision Oncology: Evolving Clinical Trials across Tumor Types. Cancers 15 (7) (2023)
Apostolia-Maria Tsimberidou, Mehmet A Baysal, Abhishek Shankar, Borje S Andersson
Autologous engineered T cell receptor therapy in advanced cancer. Human vaccines & immunotherapeutics 19 (3) (2023)
Apostolia-Maria Tsimberidou, Mehmet A Baysal, Abhishek Shankar, Borje S Andersson
Autologous engineered T cell receptor therapy in advanced cancer. Human vaccines & immunotherapeutics 19 (3) (2023)